NCT00344526
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis treatment 3 completed NCT02312206
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis treatment 3 terminated NCT01078454
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis treatment 3 completed NCT00006251
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer treatment 1 / 2 completed NCT00890747
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy treatment 1 completed NCT01849783
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma treatment 2 completed NCT00224393
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis treatment 2 completed NCT02207556
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial treatment 2 completed NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction treatment 1 completed NCT00014235
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies treatment Not Available completed NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Not Available Not Available completed NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer treatment Not Available completed NCT01728259
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD treatment 1 terminated NCT01072773
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis treatment 2 completed NCT01053494
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer No drug interventions supportive_care Not Available completed NCT01194791
Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed treatment 2 completed NCT00520767
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease treatment 2 completed NCT00536601
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors treatment Not Available completed NCT00030381
Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis No drug interventions treatment 1 terminated NCT03499808
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis treatment 2 active_not_recruiting NCT01511263
Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis treatment 2 terminated NCT03923920
Screening for Systemic Amyloidosis Via the Ligamentum Flavum No drug interventions Not Available Not Available completed NCT01531751
High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease No drug interventions treatment 2 withdrawn NCT01510613
Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis treatment 2 completed NCT03886155
Cardiac Amyloidosis Screening at Trigger Finger Release No drug interventions Not Available Not Available completed NCT02641145
Molecular Imaging of Primary Amyloid Cardiomyopathy No drug interventions diagnostic Not Available recruiting NCT01707264
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis treatment 1 / 2 completed NCT00651937
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden treatment 2 completed NCT00807872
Radioimmunoimaging of AL Amyloidosis diagnostic 1 completed NCT02555969
Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis No drug interventions Not Available Not Available completed NCT00883623
A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis treatment 2 completed NCT04504825
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis treatment 3 active_not_recruiting NCT06649695
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis No drug interventions treatment 2 not_yet_recruiting NCT04617925
A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis treatment 2 active_not_recruiting NCT04512235
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis treatment 3 active_not_recruiting NCT05199337
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis No drug interventions treatment 1 / 2 completed NCT02841033
Daratumumab for the Treatment of Patients With AL Amyloidosis treatment 1 / 2 completed NCT06205953
A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA) No drug interventions Not Available Not Available recruiting NCT06569147
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis treatment 1 / 2 not_yet_recruiting NCT04754945
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis treatment 1 active_not_recruiting NCT05066607
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy treatment 2 recruiting NCT06065852
National Registry of Rare Kidney Diseases No drug interventions Not Available Not Available recruiting NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders No drug interventions treatment Not Available recruiting NCT04895917
Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis treatment 2 active_not_recruiting NCT03431896
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis No drug interventions Not Available Not Available active_not_recruiting NCT01815086
Radioimmunoimaging of Light Chain (AL) Amyloidosis diagnostic 1 completed NCT06022939
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis treatment 3 recruiting NCT01408225
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource No drug interventions Not Available Not Available recruiting NCT04984330
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease treatment 0 withdrawn NCT01409148
Radioimmunoimaging of AL Amyloidosis diagnostic 1 completed NCT02574676
Quality of Life (QOL) Registry for Patients With AL Amyloidosis No drug interventions Not Available Not Available completed NCT03000660
Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis treatment 1 terminated NCT03236792
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis treatment 1 / 2 completed NCT04304144
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis treatment 2 completed NCT06186167
Amyloidosis Incidence in High-Risk Cardiac Device Patients No drug interventions Not Available Not Available recruiting NCT06383143
Promoting Diagnosis and Management of AL in Italy (ProDigALIty) No drug interventions Not Available Not Available recruiting NCT04839003
A Registry of AL Amyloidosis (ReAL) No drug interventions Not Available Not Available recruiting NCT06192979
Optimize First-line Treatment for AL Amyloidosis With t (11; 14) treatment Not Available recruiting NCT01570387
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis treatment 1 / 2 completed NCT04847453
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis treatment 1 recruiting NCT04937777
A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe No drug interventions Not Available Not Available completed NCT03154047
Study in Subjects With Light Chain (AL) Amyloidosis treatment 2 terminated NCT02257905
Allo SCT in Amyloidosis Non-interventional Study No drug interventions Not Available Not Available completed NCT05277493
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab No drug interventions Not Available Not Available recruiting NCT05451771
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis treatment 1 / 2 recruiting NCT05184088
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis diagnostic 3 recruiting NCT04115956
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis treatment 1 terminated NCT03618537
Ixazomib Maintenance Study in Patients With AL Amyloidosis treatment 2 active_not_recruiting NCT02489500
Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib treatment 3 terminated NCT04270175
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab treatment 2 recruiting NCT01277016
A Trial for Systemic Light-chain (AL) Amyloidosis treatment 3 completed NCT05145816
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis treatment 1 / 2 recruiting NCT02632786
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis treatment 2 completed NCT03315026
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis treatment 2 active_not_recruiting NCT05028374
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies No drug interventions treatment 2 completed NCT02613182
Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis treatment 2 terminated NCT01222260
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis treatment 2 completed NCT04392960
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis diagnostic Not Available recruiting NCT04210791
Autologous Stem Cell Transplantation for Patients With AL Amyloidosis No drug interventions Not Available Not Available enrolling_by_invitation NCT05898646
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial treatment 2 recruiting NCT05486481
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) treatment 1 / 2 recruiting NCT04943302
Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis treatment 2 withdrawn NCT06629818
Daratumumab Combined with Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14) treatment 2 not_yet_recruiting NCT04973137
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis treatment 3 recruiting NCT06097832
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis No drug interventions treatment 1 recruiting NCT04316442
Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis No drug interventions treatment 1 / 2 recruiting NCT05996406
Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) treatment 2 active_not_recruiting NCT02015312
A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) treatment 2 completed NCT06376214
Daratumumab for Patients With Light Chain Amyloidosis treatment Not Available recruiting NCT05692908
An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis No drug interventions treatment 1 withdrawn NCT01318902
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis treatment 1 completed NCT05978661
FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis No drug interventions treatment 1 recruiting